The burgeoning landscape of emerging treatments for metabolic management has seen the rise of both retatrutide and tirzepatide, both dual mechanism agonists targeting the GLP-1 and GIP receptors. While sharing a https://iowa-bookmarks.com/story16537902/retatrutide-vs-tirzepatide-a-comparative-analysis